529 filings
Page 2 of 27
4
xjm4t4ls2ae7wu03j7ks
9 Feb 24
Syndax Pharmaceuticals / Martin H. Jr. Huber ownership change
4:04pm
4
9tij 7qnb
9 Feb 24
Syndax Pharmaceuticals / Jennifer Jarrett ownership change
4:04pm
4
2wi45t0gfb5by0i9
9 Feb 24
Syndax Pharmaceuticals / Keith Katkin ownership change
4:04pm
4
t2e6 yd51
9 Feb 24
Syndax Pharmaceuticals / William Meury ownership change
4:04pm
4
4upcoungr zo2odtz
9 Feb 24
Syndax Pharmaceuticals / Briggs Morrison ownership change
4:04pm
4
i2xphy
9 Feb 24
Syndax Pharmaceuticals / Dennis Podlesak ownership change
4:04pm
4
fcm7asjhn4u48rii
9 Feb 24
Syndax Pharmaceuticals / Pierre Legault ownership change
4:04pm
SC 13G/A
wh9hu1ckzclbh
8 Feb 24
Syndax Pharmaceuticals / WELLINGTON MANAGEMENT ownership change
10:18am
SC 13G/A
upt4b5q jfr9
25 Jan 24
Syndax Pharmaceuticals / BlackRock ownership change
4:59pm
SC 13G/A
8if4n7d2f ge
25 Jan 24
Syndax Pharmaceuticals / STATE STREET ownership change
11:20am
8-K
7aczoz8x9rx11grni4t4
20 Dec 23
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
8:40am
8-K
nfdgt2fcyz
15 Dec 23
Entry into a Material Definitive Agreement
5:29pm
424B5
ezw0mizlxdor8 8s
15 Dec 23
Prospectus supplement for primary offering
5:29pm
424B5
8l22vq t7
14 Dec 23
Prospectus supplement for primary offering
4:30pm
8-K
12tg2ggpp5rn
12 Dec 23
Other Events
4:05pm
UPLOAD
bslip5pvdjs9rwfhpwa
7 Dec 23
Letter from SEC
12:00am
CORRESP
khwl df5o
28 Nov 23
Correspondence with SEC
12:00am
UPLOAD
0cs1bhhat9 paf0s9
13 Nov 23
Letter from SEC
12:00am
8-K
e2f dlbp8c5hrb7
2 Nov 23
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
4:03pm